NeOnc Technologies disclosed positive Phase 2a data for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, reporting six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark (p=0.0047). The company also shared overall survival figures and treatment continuity in a small open-label cohort, with a plan to request a Type B meeting with the FDA on a registrational path. The update is notable because it pushes a small biopharma’s candidate toward a potential development inflection point. Still, the dataset’s size and open-label design keep translation risk in view, setting up an immediate emphasis on how a future controlled trial could validate the signal.